Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers – JSPR
Pomerantz LLP filed a class action lawsuit against Jasper Therapeutics, alleging false and misleading statements regarding its drug development and manufacturing processes.Summary
Pomerantz LLP announced a class action lawsuit filed against Jasper Therapeutics, Inc. and certain officers, alleging violations of federal securities laws between November 30, 2023, and July 3, 2025. The lawsuit claims that Jasper made false and misleading statements regarding its controls over third-party manufacturers, leading to compromised drug product lots and negatively impacting clinical trial results for briquilimab, a drug candidate for mast cell-driven diseases like Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, and Asthma. Specifically, issues with a drug product lot used in clinical studies caused the company to halt development in asthma and SCID, implement cost-cutting measures, and undergo a corporate reorganization, resulting in a significant stock price drop. Investors who purchased Jasper securities during the Class Period have until November 18, 2025, to seek appointment as Lead Plaintiff.
(Source：FinancialContent)